Last reviewed · How we verify
Fluticasone/Salmeterol Discus 250/50 µg
Fluticasone/Salmeterol Discus 250/50 µg is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance therapy in patients ≥4 years old, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.
Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance therapy in patients ≥4 years old, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Fluticasone/Salmeterol Discus 250/50 µg |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance therapy in patients ≥4 years old
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Muscle cramps
- Nervousness/anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone/Salmeterol Discus 250/50 µg CI brief — competitive landscape report
- Fluticasone/Salmeterol Discus 250/50 µg updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Fluticasone/Salmeterol Discus 250/50 µg
What is Fluticasone/Salmeterol Discus 250/50 µg?
How does Fluticasone/Salmeterol Discus 250/50 µg work?
What is Fluticasone/Salmeterol Discus 250/50 µg used for?
Who makes Fluticasone/Salmeterol Discus 250/50 µg?
What drug class is Fluticasone/Salmeterol Discus 250/50 µg in?
What development phase is Fluticasone/Salmeterol Discus 250/50 µg in?
What are the side effects of Fluticasone/Salmeterol Discus 250/50 µg?
What does Fluticasone/Salmeterol Discus 250/50 µg target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance therapy in patients ≥4 years old
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy